CRVS News and Press, Corvus Pharmaceuticals Inc. From 09/07/23

2023-09-07 13:24:40 ET Gainers: Solowin Holdings SWIN +174% . Wheeler Real Estate Investment Trust WHLR +50% . Rosecliff Acquisition Corp I ( RCLF ) +47% . Semantix ( STIX ) +41% . Hitek Global ( HKIT ) +21% . Biodexa Pharmaceuticals...

2023-09-06 17:05:09 ET Gainers: Calavo Growers ( CVGW ) +9% . Corvus Pharmaceuticals ( CRVS ) +7% . EDAP TMS  ( EDAP ) +6% . Evelo Biosciences ( EVLO ) +5% . Rover Group ( ROVR ) +4% . Losers: Sportsman's Warehouse (...

Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clini...

2023-08-18 14:20:52 ET More on Corvus Circling Back On Corvus Pharmaceuticals Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China Corvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China Corvus P...

2023-08-08 21:57:12 ET Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript August 08, 2023 04:30 PM ET Company Participants Zack Kubow - IR-Real Chemistry Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Roger Song - J...

2023-08-08 16:49:20 ET Corvus Pharmaceuticals press release ( NASDAQ: CRVS ): Q2 GAAP EPS of -$0.14 in-line. As of June 30, 2023, Corvus had cash, cash equivalents and marketable securities of $37.0 million as compared to $42.3 million as of December 31, 2022. F...

Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and solid tumors Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Cali...

2023-08-01 15:53:10 ET Summary Today, we take our first new look at a small biopharma firm called Corvus Pharmaceuticals in over 18 months. The company is getting closer to moving its primary drug candidate into a potentially pivotal trial to treat a form of T-cell lymphoma. A...

BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update an...

Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumors Soquelitinib shown to increase infiltration of cancer killing T cells with greater potency and less resistance due to exhaustion BURLINGAME, Calif.,...